Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

154 clinical studies listed.

Filters:

Metastatic Cancer

Tundra lists 154 Metastatic Cancer clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06771219

SLV-154 Treatment of Advanced Cancers

This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

Gender: All

Ages: 12 Years - Any

Updated: 2026-11-20

8 states

Advanced Cancer
Advanced Solid Tumor
Metastatic Cancer
ACTIVE NOT RECRUITING

NCT05267626

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-20

11 states

Advanced Solid Tumor
Metastatic Cancer
Cutaneous Melanoma
+1
RECRUITING

NCT07621471

IL-15 Enhanced NK Cell Therapy for Solid Tumors

A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.

Gender: All

Ages: 18 Years - 70 Years

Updated: 2026-11-20

Solid Tumors
Metastatic Cancer
COMPLETED

NCT02593578

Molecular Profiling-Guided Targeted Therapy in Patients With Advanced Cancer

The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information. Therefore, a big data of genome-clinical information is important. To determine the feasibility of the use of tumor's molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(Response rate,PFS, duration of response and overall survival )of patients with advanced cancer, the investigators are going to take a tumor tissue of patients and process molecular profiling and receive molecular profile directed treatments.

Gender: All

Ages: 19 Years - Any

Updated: 2026-11-19

Metastatic Cancer
RECRUITING

NCT05208047

(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-19

27 states

Advanced Gastrointestinal Stromal Tumors
Metastatic Cancer
RECRUITING

NCT02646228

Establishment of Patient Derived Cancer Cell Models to Interrogate Novel Molecular Targets in Metastatic Cancer

With rapid advances in molecular oncology, the availability of preclinical in vitro cell models and in vivo animal models with specific genomic aberrations is critical for improved prediction of clinical outcomes in cancer patients. One of the most widely used preclinical models is conventional cell lines, such as the NCI-60 panel of cell lines;these cell lines are widely used in preclinical testing for novel targeted drugs, partially owing to the low expense and reduced labor associated with cell culture compared with other preclinical models, such as animal xenografts. However, recent studies have shown that accumulation of genetic aberrations in cancer cell lines occurs with increasing passage number. These models also lack the heterogeneity of tumors and do not exhibit a proper microenvironment, highlighting the limitations of cell-based models. Consistent with this, Johnson et al. demonstrated that in vivo activities of the cell lines within the NCI-60 panel did not closely correlate with corresponding human cancers. Therefore, to better preserve the genomic integrity and tumor heterogeneity observed in patients, patient-derived xenograft (PDX) models are being used more frequently. PDX is generated by directly transplanting freshly resected patient tumors into immunocompromised murine hosts with or without an intermediate in vitro culture step. This PDX model is an improvement over cell lines because it can provide both an appropriate tumor microenvironment and heterogeneity of tumor cells. However, the engraftment success rates and growth rates of implanted tumors are highly variable depending on the tumor type, possibly due to insufficient numbers of hematopoietic cells and/or ineffective microenvironmental cues in the mouse stroma. The extent to which tumor cells from freshly resected tumors are able to withstand mechanical stresses and xenotransplantation barriers is also unclear. Furthermore, the use of PDX models for application in clinical oncology is limited owing to the time required for PDX establishment (\> 4 months) since most patients with refractory cancer live less than 1 year. Recently, PDC line models have been suggested as an alternative preclinical model to be used as a prediction tool for preclinical drug sensitivity. Therefore, in this study, the investigators aimed to overcome these potential barriers of pre-existing models by examining the capacity of PDC line models to recapitulate the histological and genomic features of primary patient tumors. In selected cases, the investigators screened drug sensitivity in vitro using PDC lines and compared the results with real-life clinical treatment outcomes.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

1 state

Metastatic Cancer
RECRUITING

NCT06165419

Definitive Radiation for High-Risk Spine Metastases

This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

1 state

Metastatic Cancer
Metastatic Lung Cancer
Metastatic Breast Cancer
+5
COMPLETED

NCT04666688

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or tislelizumab in Patients with Metastatic Solid Tumors

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-16

9 states

Metastatic Cancer
Solid Tumor
Head and Neck Cancer
NOT YET RECRUITING

NCT07937423

DYNAMIC Pilot Optimization Trial

The purpose of this pilot optimization trial is to evaluate the feasibility and acceptability of using an optimization approach to refine DYNAMIC, a behavioral intervention designed to improve psychosocial well-being among young adults ages 25-39 with advanced cancer. This study is guided by the Multiphase Optimization Strategy (MOST) framework. Participants will be randomized using a 2x2x2 factorial design to receive up to three DYNAMIC intervention components: relaxation training (yes/no), cognitive behavioral therapy-based skills training (yes/no), and young-adult relevant health education (yes/no).

Gender: All

Ages: 25 Years - 39 Years

Updated: 2026-11-16

2 states

Advanced Cancer
Metastatic Cancer
Cancer Survivorship
ENROLLING BY INVITATION

NCT00068003

Harvesting Cells for Experimental Cancer Treatments

Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will collect white blood cells from normal volunteers and white blood cells and/or tumor cells, from patients who have been screened for and are eligible for a NCI Surgery Branch treatment protocol. The cells collected from normal volunteers will be used as growth factors for the cells during the period of laboratory growth. The cells and/or tumor from patients will be used to make the cell treatment product. Eligibility: Patients must be eligible for a NCI Surgery Branch Treatment Protocol Normal Volunteers must meet the criteria for blood donation Design Both patients and normal Volunteers will undergo apheresis. Patients will then undergo further testing as required by the treatment protocol. There is no required follow up for normal volunteers. ...

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-12

1 state

Melanoma
Gastrointestinal Cancer
Metastatic Cancer
+2
COMPLETED

NCT04739618

Metastatic Solid Cancer Clinical Trial

This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-12

2 states

Metastatic Cancer
ACTIVE NOT RECRUITING

NCT04390724

Optimizing Y90 Therapy for Radiation Lobectomy

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-12

2 states

HCC
Resection
Transplant
+2
RECRUITING

NCT05394103

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-09

7 states

Advanced Cancer
Metastatic Cancer
ACTIVE NOT RECRUITING

NCT06630845

Comparison of Whole Body DWI to FDG PET

This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-09

1 state

Metastatic Cancer
RECRUITING

NCT05283044

Implementing Precision Medicine in cOmmunity HospiTALs

This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-06

Metastatic Cancer
TERMINATED

NCT04648202

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-05

6 states

Advanced Cancer
Metastatic Cancer
ACTIVE NOT RECRUITING

NCT04740424

FS222 First in Human Study in Patients With Advanced Malignancies

This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222. This is a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS222 in participants with advanced tumours. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-04

8 states

Advanced Cancer
Metastatic Cancer
ACTIVE NOT RECRUITING

NCT05502315

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).

Gender: MALE

Ages: 18 Years - Any

Updated: 2026-11-02

4 states

Castration-resistant Prostate Cancer
Metastatic Cancer
RECRUITING

NCT05475171

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-02

1 state

Metastatic Cancer
Cervical Cancer
RECRUITING

NCT06242470

A Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion in Module A of the study. Combination therapy with pembrolizumab will occur in Module B of the study Participants will receive vobramitamab tavatecan by intravenous (IV) infusion. The dose of vobramitamab tavatecan will be assigned at the time of enrollment. Pembrolizumab will be administered at 200 mg every 3 weeks. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood and tumor samples collected for research purposes.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-28

9 states

Advanced Solid Tumor
Advanced Cancer
Metastatic Cancer
+19
COMPLETED

NCT05103358

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Gender: All

Ages: 12 Years - Any

Updated: 2026-10-28

34 states

Tumor
Tumor, Solid
Metastasis
+18
RECRUITING

NCT05686226

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-28

2 states

Cervical Cancer
Throat Cancer
Oropharynx Cancer
+18
RECRUITING

NCT06174987

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-26

2 states

Advanced Cancer
Metastatic Cancer
ACTIVE NOT RECRUITING

NCT05010629

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: * 9-ING-41 (a GSK-3β inhibitor) * Carboplatin chemotherapy

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-23

1 state

Salivary Gland Cancer
Recurrent Salivary Gland Cancer
Metastatic Cancer
+1